Ignite Creation Date:
2024-05-06 @ 6:21 PM
Last Modification Date:
2024-10-26 @ 2:46 PM
Study NCT ID:
NCT05638594
Status:
RECRUITING
Last Update Posted:
2023-03-20
First Post:
2022-11-24
Brief Title:
Pyrotinib Combined With Trastuzumab Dalpiciclib Letrozole Versus TCbHP Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin as Neoadjuvant Treatment in HR HER2 Breast Cancer
Sponsor:
Shengjing Hospital
Organization:
Shengjing Hospital
Study Overview
Official Title:
A Randomized Controlled Open-label Multicenter Clinical Study of Pyrotinib Maleate Combined With TrastuzumabDalpiciclib and Letrozole Versus Trastuzumab Combined With Pertuzumab Docetaxel and Carboplatin as Neoadjuvant Therapy for Stage II-III HR HER2 Breast Cancer
Status:
RECRUITING
Status Verified Date:
2023-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an investigator-initiated randomized controlled open-label multicenter prospective Phase 2 clinical study Patients with stage II-III HR HER2 breast cancer were randomly divided into two groups at a ratio of 11 The experimental group received pyrotinib combined with trastuzumab dalpiciclib and letrozole the control group received trastuzumab combined with pertuzumab docetaxel and carboplatin The main study objective was to evaluate the efficacy and safety of neoadjuvant therapy for HR HER2 breast cancer in the two groups
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None